CDT Equity engages NJS Foresight Bio-Advisory for out-licensing strategy

CDT Equity (CDT) engaged NJS Foresight Bio-Advisory to identify, source and support the execution of out-licensing opportunities for selected assets within its solid-form patent portfolio. The engagement is intended to expand CDT’s commercial reach and accelerate potential licensing and royalty-based transactions.